Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer

BACKGROUND: The multicenter, open‐label, randomized, phase III EPIC study (EMR 062202‐025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor–detectable metastatic colorectal cancer (mCRC) that progressed on first‐line fluoropyrimidine‐ and oxa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Sobrero, Alberto, Lenz, Heinz‐Josef, Eng, Cathy, Scheithauer, Werner, Middleton, Gary, Chen, Wenfeng, Esser, Regina, Nippgen, Johannes, Burris, Howard
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873334/
https://ncbi.nlm.nih.gov/pubmed/33191588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13591
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares